ArticleClinical cancer research : an official journal of the American Association for Cancer Research2010
Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 132 citations in OpenAlex.
- Regulation of histones in thromboinflammation.Frontiers in immunology · 2026Review
- Revisiting Glomerulopathy in Clusterin Knockout Mice: A Mouse Model of Human Immunotactoid Glomerulopathy.Nephrology (Carlton, Vic.) · 2025Article
- Retinal Pigment Epithelium Under Oxidative Stress: Chaperoning Autophagy and Beyond.International journal of molecular sciences · 2025Review
- Review
- Clusterin Expression in Colorectal Carcinomas.International journal of molecular sciences · 2023Review
- The Ins and Outs of Clusterin: Its Role in Cancer, Eye Diseases and Wound Healing.International journal of molecular sciences · 2023Review
- Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?Cancers · 2021Review
- Clinical importance of serum secreted clusterin in predicting invasive breast cancer and treatment responses.Bioengineered · 2021Article
- N-cadherin upregulation mediates adaptive radioresistance in glioblastoma.The Journal of clinical investigation · 2021Article
- Clusterin Protects Lipotoxicity-Induced Apoptosis via Upregulation of Autophagy in Insulin-Secreting Cells.Endocrinology and metabolism (Seoul, Korea) · 2020Article
- From Analysis of Ischemic Mouse Brain Proteome to Identification of Human Serum Clusterin as a Potential Biomarker for Severity of Acute Ischemic Stroke.Translational stroke research · 2019Article
- Verteporfin blocks Clusterin which is required for survival of gastric cancer stem cell by modulating HSP90 function.International journal of biological sciences · 2019Article
- A Role for Clusterin in Exfoliation Syndrome and Exfoliation Glaucoma?Journal of glaucoma · 2018Review
- SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1.EMBO molecular medicine · 2018Article
- Circulating ApoJ is closely associated with insulin resistance in human subjects.Metabolism: clinical and experimental · 2018Article
- Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model.Targeted oncology · 2017Article
- Circulating Clusterin and Osteopontin Levels in Asthma and Asthmatic Pregnancy.Canadian respiratory journal · 2017Article
- The role of chemotherapy and new targeted agents in the management of primary prostate cancer.Journal of clinical urology · 2016Article
- Overcoming HSP27-mediated resistance by altered dimerization of HSP27 using small molecules.Oncotarget · 2016Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Many strategies used to kill cancer cells induce stress-responses that activate survival pathways to promote emergence of a treatment resistant phenotype. Secretory clusterin (sCLU) is a stress-activated cytoprotective chaperone up-regulated by many varied anticancer therapies to confer treatment resistance when overexpressed. sCLU levels are increased in several treatment recurrent cancers including castrate resistant prostate cancer, and therefore sCLU has become an attractive target in cancer therapy. sCLU is not druggable with small molecule inhibitors, therefore nucleotide-based strategies to inhibit sCLU at the RNA level are appealing. Preclinical studies have shown that antisense oligonucleotide (ASO) or siRNA knockdown of sCLU have preclinical activity in combination with hormone- and chemotherapy. Phase I and II clinical trial data indicate that the second generation ASO, custirsen (OGX-011), has biologic and clinical activity, suppressing sCLU expression in prostate cancer tissues by more than 90%. A randomized study comparing docetaxel-custirsen to docetaxel alone in men with castrate resistant prostate cancer reported improved survival by 7 months from 16.9 to 23.8 months. Strong preclinical and clinical proof-of-principle data provide rationale for further study of sCLU inhibitors in randomized phase III trials, which are planned to begin in 2010.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.